Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06609889 · ClinicalTrials.gov registry record · Phase 1
A Safety and Efficacy of Intrathecally Administered ION283 in Patients With Lafora Disease
A Phase 1 study of Lafora Disease, sponsored by Berge Minassian.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT06609889 is a Phase 1 study of Lafora Disease that is actively recruiting participants, run by Berge Minassian. The registered enrollment target is 10 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06609889, a Phase 1 study of Lafora Disease, is actively recruiting participants, sponsored by Berge Minassian.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will test the safety and efficacy of multiple doses of ION283 administered as intrathecal (IT) injections by lumbar puncture (LP). All subjects will receive ION283. The dose level of 15 mg will be studied in all subjects.
Conditions Studied
Interventions
- GENETIC ION283
Study Locations (1)
Texas
- Childrens Health - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2024-12-03 |
| Est. Completion | 2028-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06609889
The ClinicalTrials.gov registry entry for NCT06609889 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Berge Minassian, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lafora Disease appearing as the primary indexed condition, and to 1 intervention - of which ION283 is the first listed.
NCT06609889 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06609889 about?
NCT06609889 is a clinical study titled "A Safety and Efficacy of Intrathecally Administered ION283 in Patients With Lafora Disease". This study will test the safety and efficacy of multiple doses of ION283 administered as intrathecal (IT) injections by lumbar puncture (LP). All subjects will receive ION283. The dose level of 15 mg will be studied in all subjects.
What is the current status of trial NCT06609889?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2024-12-03. Estimated completion is 2028-10.
What conditions does trial NCT06609889 study?
This clinical trial studies the following conditions: Lafora Disease.
What interventions are being tested in trial NCT06609889?
The interventions under investigation include: ION283 (GENETIC).
Who is sponsoring clinical trial NCT06609889?
This trial is sponsored by Berge Minassian, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06609889 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.